Interferons, immunity and cancer immunoediting

[1]  J. Grandis,et al.  Decreased STAT1 expression by promoter methylation in squamous cell carcinogenesis. , 2007, Journal of the National Cancer Institute.

[2]  R. Schreiber,et al.  Blocking monoclonal antibodies specific for mouse IFN-alpha/beta receptor subunit 1 (IFNAR-1) from mice immunized by in vivo hydrodynamic transfection. , 2006, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[3]  Z. Trajanoski,et al.  Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome , 2006, Science.

[4]  T. Mcclanahan,et al.  IL-23 promotes tumour incidence and growth , 2006, Nature.

[5]  Seiya Kato,et al.  IFNγ-dependent, spontaneous development of colorectal carcinomas in SOCS1-deficient mice , 2006, The Journal of experimental medicine.

[6]  S. Gasser,et al.  The DNA damage response arouses the immune system. , 2006, Cancer research.

[7]  Y. Hiraku,et al.  Oxidative and nitrative DNA damage in animals and patients with inflammatory diseases in relation to inflammation-related carcinogenesis , 2006, Biological chemistry.

[8]  J. Derisi,et al.  Identification of a Novel Gammaretrovirus in Prostate Tumors of Patients Homozygous for R462Q RNASEL Variant , 2006, PLoS pathogens.

[9]  R. Schreiber,et al.  IFN-Dependent Down-Regulation of the NKG2D Ligand H60 on Tumors1 , 2006, The Journal of Immunology.

[10]  Gavin P Dunn,et al.  Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. , 2006, Advances in immunology.

[11]  L. Coussens,et al.  Paradoxical roles of the immune system during cancer development , 2006, Nature Reviews Cancer.

[12]  M. Smyth,et al.  Cutting Edge: TRAIL Deficiency Accelerates Hematological Malignancies1 , 2005, The Journal of Immunology.

[13]  R. Schreiber,et al.  IFN-γ Controls the Generation/Activation of CD4+CD25+ Regulatory T Cells in Antitumor Immune Response1 , 2005, The Journal of Immunology.

[14]  J. Becker,et al.  STAT5 Contributes to Interferon Resistance of Melanoma Cells , 2005, Current Biology.

[15]  M. Smyth,et al.  NKG2D function protects the host from tumor initiation , 2005, The Journal of experimental medicine.

[16]  G. Willimsky,et al.  Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance , 2005, Nature.

[17]  T. Decker,et al.  The Yin and Yang of type I interferon activity in bacterial infection , 2005, Nature Reviews Immunology.

[18]  R. Schreiber,et al.  A critical function for type I interferons in cancer immunoediting , 2005, Nature Immunology.

[19]  L. Old,et al.  Accelerated chemically induced tumor development mediated by CD4+CD25+ regulatory T cells in wild-type hosts. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[20]  L. Platanias.  Mechanisms of type-I- and type-II-interferon-mediated signalling , 2005, Nature Reviews Immunology.

[21]  R. Schreiber,et al.  IFN unresponsiveness in LNCaP cells due to the lack of JAK1 gene expression. , 2005, Cancer research.

[22]  J. Darnell,et al.  Transcriptionally active Statl is required for the antiproliferative effects of both interferon a and interferon , 2005 .

[23]  C. Bogdan,et al.  The role of type I interferons in non‐viral infections , 2004, Immunological reviews.

[24]  K. Murphy,et al.  Issues in T‐helper 1 development – resolved and unresolved , 2004, Immunological reviews.

[25]  C. D. Krause,et al.  Interferons, interferon‐like cytokines, and their receptors , 2004, Immunological reviews.

[26]  J. Hess,et al.  Enhanced tumorigenesis in HTLV-1 tax-transgenic mice deficient in interferon-gamma. , 2004, Blood.

[27]  C. Poremba,et al.  Expression of SOCS-1, suppressor of cytokine signalling-1, in human melanoma. , 2004, The Journal of investigative dermatology.

[28]  Hong Wu,et al.  PIAS1 selectively inhibits interferon-inducible genes and is important in innate immunity , 2004, Nature Immunology.

[29]  R. Schreiber,et al.  The immunobiology of cancer immunosurveillance and immunoediting. , 2004, Immunity.

[30]  K. Kinzler,et al.  Cancer genes and the pathways they control , 2004, Nature Medicine.

[31]  R. Schreiber,et al.  The three Es of cancer immunoediting. , 2004, Annual review of immunology.

[32]  M. Smyth,et al.  Innate Immune Surveillance of Spontaneous B Cell Lymphomas by Natural Killer Cells and γδ T Cells , 2004, The Journal of experimental medicine.

[33]  C. Constantinides,et al.  The immunomodulating effect of interferon-gamma intravesical instillations in preventing bladder cancer recurrence. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[34]  A. Hayday,et al.  The Distinct Contributions of Murine T Cell Receptor (TCR)γδ+ and TCRαβ+ T Cells to Different Stages of Chemically Induced Skin Cancer , 2003, The Journal of experimental medicine.

[35]  H. Ikeda,et al.  CD4+ CD25+ T cells responding to serologically defined autoantigens suppress antitumor immune responses , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[36]  Wancai Yang,et al.  γδ T Cells Provide an Early Source of Interferon γ in Tumor Immunity , 2003, The Journal of experimental medicine.

[37]  Hideo Negishi,et al.  Integration of interferon-α/β signalling to p53 responses in tumour suppression and antiviral defence , 2003, Nature.

[38]  G. Forni,et al.  α-Galactosylceramide (KRN7000) suppression of chemical- and oncogene-dependent carcinogenesis , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[39]  G. Lesinski,et al.  The antitumor effects of IFN-α are abrogated in a STAT1-deficient mouse , 2003 .

[40]  F. Alt,et al.  Deficiencies of GM-CSF and Interferon γ Link Inflammation and Cancer , 2003, Journal of Experimental Medicine.

[41]  R. Silverman.  Implications for RNase L in prostate cancer biology. , 2003, Biochemistry.

[42]  R. Schreiber,et al.  CHAPTER 24 – Interferon-γ , 2003 .

[43]  J. Witte,et al.  RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases , 2002, Nature Genetics.

[44]  William C Hahn,et al.  Rules for making human tumor cells. , 2002, The New England journal of medicine.

[45]  R. Schreiber,et al.  Cancer immunoediting: from immunosurveillance to tumor escape , 2002, Nature Immunology.

[46]  J. Folkman,et al.  Clinical translation of angiogenesis inhibitors , 2002, Nature Reviews Cancer.

[47]  M. Smyth,et al.  A Critical Role for Natural Killer T Cells in Immunosurveillance of Methylcholanthrene-induced Sarcomas , 2002, The Journal of experimental medicine.

[48]  J. Trapani,et al.  Suppression of Lymphoma and Epithelial Malignancies Effected by Interferon γ , 2002, The Journal of experimental medicine.

[49]  Lloyd J. Old,et al.  The roles of IFNγ in protection against tumor development and cancer immunoediting , 2002 .

[50]  J. Kirkwood,et al.  Interferon-alpha in tumor immunity and immunotherapy. , 2002, Cytokine & growth factor reviews.

[51]  B. Bardot,et al.  Enhanced tumor development in mice lacking a functional type I interferon receptor. , 2002, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[52]  M. Grace,et al.  Interferon‐α as an immunotherapeutic protein , 2002, Journal of Leukocyte Biology.

[53]  M. Smyth,et al.  Increased Susceptibility to Tumor Initiation and Metastasis in TNF-Related Apoptosis-Inducing Ligand-Deficient Mice1 , 2002, The Journal of Immunology.

[54]  K. Klinger,et al.  Germline mutations in the ribonuclease L gene in families showing linkage with HPC1 , 2002, Nature Genetics.

[55]  M. Smyth,et al.  Critical Role for Tumor Necrosis Factor–related Apoptosis-inducing Ligand in Immune Surveillance Against Tumor Development , 2002, The Journal of experimental medicine.

[56]  Takuma Hayashi,et al.  Development of spontaneous uterine tumors in low molecular mass polypeptide-2 knockout mice. , 2002, Cancer research.

[57]  A. Hayday,et al.  Regulation of Cutaneous Malignancy by γδ T Cells , 2001, Science.

[58]  R. Schreiber,et al.  IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity , 2001, Nature.

[59]  J. J. Zhang,et al.  Identification of two residues in MCM5 critical for the assembly of MCM complexes and Stat1-mediated transcription activation in response to IFN-γ , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[60]  G. Beatty,et al.  IFN-γ-Dependent Inhibition of Tumor Angiogenesis by Tumor-Infiltrating CD4+ T Cells Requires Tumor Responsiveness to IFN-γ1 , 2001, The Journal of Immunology.

[61]  W. El-Deiry,et al.  p53-independent upregulation of KILLER/DR5 TRAIL receptor expression by glucocorticoids and interferon-gamma. , 2001, Experimental cell research.

[62]  M. Farrar,et al.  Inhibition of Cellular Responsiveness to Interferon-y (IFNy) Induced by Overexpression of Inactive Forms of the IFNy Receptor* , 2001 .

[63]  M. Smyth,et al.  Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis. , 2001, Blood.

[64]  M. Smyth,et al.  NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma. , 2001, International immunology.

[65]  F. Fallarino,et al.  Spontaneous Rejection of Poorly Immunogenic P1.HTR Tumors by Stat6-Deficient Mice1 , 2000, The Journal of Immunology.

[66]  M. Shibamori,et al.  Tyk2 plays a restricted role in IFN alpha signaling, although it is required for IL-12-mediated T cell function. , 2000, Immunity.

[67]  H. Pircher,et al.  Partial impairment of cytokine responses in Tyk2-deficient mice. , 2000, Immunity.

[68]  J. Trapani,et al.  Perforin-Mediated Cytotoxicity Is Critical for Surveillance of Spontaneous Lymphoma , 2000, The Journal of experimental medicine.

[69]  B. Seliger,et al.  Antigen-processing machinery breakdown and tumor growth. , 2000, Immunology today.

[70]  H. Hausmaninger,et al.  Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial , 2000, British Journal of Cancer.

[71]  J. Trapani,et al.  Differential Tumor Surveillance by Natural Killer (Nk) and Nkt Cells , 2000, The Journal of experimental medicine.

[72]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[73]  F. Marincola,et al.  Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. , 2000, Advances in immunology.

[74]  W. El-Deiry,et al.  p 53-Independent Upregulation of KILLER / DR 5 TRAIL Receptor Expression by Glucocorticoids and Interferon-g , 2000 .

[75]  F. Garrido,et al.  The HLA crossroad in tumor immunology. , 2000, Human immunology.

[76]  F. Fallarino,et al.  Cutting edge: differentiation of antitumor CTL in vivo requires host expression of Stat1. , 1999, Journal of immunology.

[77]  A. Yoshimura,et al.  SOCS1 Deficiency Causes a Lymphocyte-Dependent Perinatal Lethality , 1999, Cell.

[78]  Paul J Hertzog,et al.  SOCS1 Is a Critical Inhibitor of Interferon γ Signaling and Prevents the Potentially Fatal Neonatal Actions of this Cytokine , 1999, Cell.

[79]  R. Schreiber,et al.  CD4+ T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-γ , 1999 .

[80]  G. Kollias,et al.  Mice deficient in tumor necrosis factor-α are resistant to skin carcinogenesis , 1999, Nature Medicine.

[81]  W. Ouyang,et al.  Induction of interferon‐γ production in Th1 CD4+ T cells: evidence for two distinct pathways for promoter activation , 1999 .

[82]  G. Stark,et al.  How cells respond to interferons. , 1998, Annual review of biochemistry.

[83]  A. Chong,et al.  IFN-gamma induces cell growth inhibition by Fas-mediated apoptosis: requirement of STAT1 protein for up-regulation of Fas and FasL expression. , 1998, Cancer research.

[84]  S. Pestka,et al.  Tumor cell responses to IFNgamma affect tumorigenicity and response to IL-12 therapy and antiangiogenesis. , 1998, Immunity.

[85]  R. Schreiber,et al.  Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice , 1998 .

[86]  M. Gleave,et al.  Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group. , 1998, The New England journal of medicine.

[87]  A. Eggermont,et al.  Isolated limb perfusion in primary and recurrent melanoma: indications and results. , 1998, Seminars in surgical oncology.

[88]  P. Hersey,et al.  Interferon-resistant Human Melanoma Cells Are Deficient in ISGF3 Components, STAT1, STAT2, and p48-ISGF3γ* , 1997, The Journal of Biological Chemistry.

[89]  R. Flavell,et al.  Activation of the STAT signaling pathway can cause expression of caspase 1 and apoptosis , 1997, Molecular and cellular biology.

[90]  U. Boehm,et al.  Cellular responses to interferon-gamma. , 1997, Annual review of immunology.

[91]  M Aguet,et al.  The IFN gamma receptor: a paradigm for cytokine receptor signaling. , 1997, Annual review of immunology.

[92]  J. Kirkwood,et al.  Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[93]  J. Darnell,et al.  Two contact regions between Stat1 and CBP/p300 in interferon γ signaling , 1996 .

[94]  R. Zinkernagel,et al.  Decreased tumor surveillance in perforin-deficient mice , 1996, The Journal of experimental medicine.

[95]  L. Old,et al.  Effect of interleukin 12 on tumor induction by 3-methylcholanthrene. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[96]  J. Darnell,et al.  Transcriptionally active Stat1 is required for the antiproliferative effects of both interferon alpha and interferon gamma. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[97]  Xin-Yuan Fu,et al.  Cell Growth Arrest and Induction of Cyclin-Dependent Kinase Inhibitor p21WAF1/CIP1 Mediated by STAT1 , 1996, Science.

[98]  R. Fitzgibbons,et al.  Controlled clinical trial of interferon-gamma as postoperative surgical adjuvant therapy for colon cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[99]  M. Sanda,et al.  Molecular characterization of defective antigen processing in human prostate cancer. , 1995, Journal of the National Cancer Institute.

[100]  J. Jett,et al.  Phase III trial of recombinant interferon gamma in complete responders with small-cell lung cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[101]  R. Schreiber,et al.  Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. , 1994, Immunity.

[102]  R. Schreiber,et al.  Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production. , 1994, Journal of immunology.

[103]  A. Thomson.  The cytokine handbook , 1994 .

[104]  P. Leder,et al.  IP-10, a -C-X-C- chemokine, elicits a potent thymus-dependent antitumor response in vivo , 1993, The Journal of experimental medicine.

[105]  M. Farrar,et al.  Inhibition of cellular responsiveness to interferon-gamma (IFN gamma) induced by overexpression of inactive forms of the IFN gamma receptor. , 1993, Journal of Biological Chemistry.

[106]  E. Unanue,et al.  Interleukin 12 and tumor necrosis factor alpha are costimulators of interferon gamma production by natural killer cells in severe combined immunodeficiency mice with listeriosis, and interleukin 10 is a physiologic antagonist. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[107]  J. Uhr,et al.  Cancer dormancy: studies of the murine BCL1 lymphoma. , 1991, Cancer research.

[108]  F. Belardelli,et al.  Injection of mice with antibody to interferon enhances the growth of transplantable murine tumors , 1983, The Journal of experimental medicine.

[109]  F. Belardelli,et al.  Antitumor effects of interferon in mice injected with interferon‐sensitive and interferon‐resistant friend leukemia cells. I. , 1982, International journal of cancer.

[110]  N. Minato,et al.  Influence of anti-mouse interferon serum on the growth and metastasis of tumor cells persistently infected with virus and of human prostatic tumors in athymic nude mice. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[111]  K. Weinhold,et al.  The tumor dormant state. , 1981, Advances in cancer research.

[112]  I. Gresser,et al.  Mechanism of the Antitumour Effect of Interferon in Mice , 1972, Nature.

[113]  I. Gresser,et al.  Increased survival in mice inoculated with tumor cells and treated with interferon preparations. , 1969, Proceedings of the National Academy of Sciences of the United States of America.

[114]  M. Burnet.  Cancer—A Biological Approach , 1957, British medical journal.